AstraZeneca Cancer Drug Enhertu Shows Clinically Meaningful, Durable Response in Trial
June 05 2023 - 8:53AM
Dow Jones News
By Elena Vardon
AstraZeneca said Monday that the phase II trial for its cancer
drug Enhertu showed clinically meaningful and durable responses
across patients with HER2-expressing advanced solid tumours who had
been previously treated.
The Anglo-Swedish pharma giant said interim results from its
DESTINY-PanTumor02 Phase 2 trial showed an objective response rate
of 37.1% in the trial's overall population and also demonstrated
positive antitumor activity in patients previously treated for
HER2-positive metastatic colorectal cancer.
Enhertu, or trastuzumab deruxtecan, is being jointly developed
and commercialized by AstraZeneca and Daiichi Sankyo.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
June 05, 2023 08:38 ET (12:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
From Nov 2024 to Dec 2024
Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
From Dec 2023 to Dec 2024
